Calent Tablet 50/12.5/200mg

300

Out of stock

Category:

Description

Indications 

Calent Tablet 50/12.5/200mg is primarily indicated in conditions like Dopa-responsive dystonia, Parkinsonism, Parkinson’s disease, Parkinson’s disease (but not drug-induced extrapyramidal symptoms), Restless legs syndrome, and can also be given in adjunctive therapy as an alternative drug of choice in Glucoma.

Side Effects

The severe or irreversible adverse effects of Calent Tablet 50/12.5/200mg, which give rise to further complications include Hallucinations, Hallucinations, Delirium, Dyskinesias, Mental disturbances, Cardiac irregularities, Bradyphrenia., Calent Tablet 50/12.5/200mg produces potentially life-threatening effects which include Cardiac arrhythmias, Postural hypotension, Anginal pain, Postural hypotension, which are responsible for the discontinuation of Calent Tablet 50/12.5/200mg therapy., The signs and symptoms that are produced after the acute overdosage of Calent Tablet 50/12.5/200mg include Hypotension, Nausea, vomiting, Cardiac arrhythmias, Cytotoxicity, Confusion.,The symptomatic adverse reactions produced by Calent Tablet 50/12.5/200mg are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Nausea, Vomiting, Anorexia, Diarrhea, Palpitation, Constipation, Abdominal pain, Gl upset, Elevated alkaline phosphatase, Elevated hepatic transaminases, Faintness, Discoloration of urine, Gl bleeding, dizziness, faintness.

Contraindication 

Calent Tablet 50/12.5/200mg is contraindicated in conditions like Psychosis, Narrow-angle glaucoma, Skin lesions.

Warning 

It should be used with caution in patients with glaucoma, history of skin cancer, breathing problems, heart, kidney, liver, endocrine disease, ulcers, depression or blood disorders. It should be used during pregnancy only if clearly needed. Do not take this during lactation.

Reviews

There are no reviews yet.

Be the first to review “Calent Tablet 50/12.5/200mg”

Your email address will not be published. Required fields are marked *